Home > Journals > Minerva Endocrinologica > Past Issues > Minerva Endocrinologica 2010 March;35(1) > Minerva Endocrinologica 2010 March;35(1):27-33

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA ENDOCRINOLOGICA

A Journal on Endocrine System Diseases


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,118


eTOC

 

  PANCREATIC CANCER


Minerva Endocrinologica 2010 March;35(1):27-33

language: English

Molecular therapy of pancreatic cancer

Plentz R. R., Manns M. P., Greten T. F.

Department of Gastroenterology, Hepatology and Endocrinology, Medical School Hannover, Hannover, Germany


PDF  


Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of mortality and morbidity. The 5-year survival rate remains less than 5% and in contrast to other solid tumors, survial has changed only little in the last decade. Overall PDAC treatment shows only limited response to conventional chemotherapeutic agents. Several trials on therapy are ongoing and new targeted agents are in development to improve the treatment outcome of this deadly disease. However, our review presents the current developments of molecular therapies, supports the translational PDAC research and encourage you to take part in further clinical studies.

top of page

Publication History

Cite this article as

Corresponding author e-mail

Plentz.Ruben@mh-hannover.de